



PCT/GB 2004 / 003051

REC'D 12 AUG 2004
WIPO

PCT INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, p.l.c. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 16 July 2004

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

THE PATENT OFFICE
K
15 JUL 2003

Request for grant of a patent
(See the notes on the back of this form. You can also get
an explanatory leaflet from the Patent Office to help
you fill in this form)

The
Patent
Office

1/77
15JUL03 E822571-1 D10108
P01/7700 0.00-0316467.0

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

15 JUL 2003

1. Your reference

MPD364/GB/RGMS

2. Patent application number

(The Patent Office will fill in this part)

0316467.0

3. Full name, address and postcode of the or of
each applicant (underline all surnames)

HUNTSMAN INTERNATIONAL LLC a limited liability
Company formed under the laws of Delaware, USA
500 HUNTSMAN WAY
SALT LAKE CITY
UTAH 84108

Patents ADP number (if you know it)

If the applicant is a corporate body, give the
country/state of its incorporation

UNITED STATES OF AMERICA

8172223001

4. Title of the invention

STRUCTURED SURFACTANT SYSTEMS

5. Name of your agent (if you have one)

R-C-M SAVIDGE

BARRY BLETCH

HUNTSMAN SURFACE SCIENCES UK LIMITED
PATENTS DEPARTMENT
210-222 HAGLEY ROAD WEST
OLDBURY
WEST MIDLANDS B68 0WA

138 HAGLEY ROAD
EDGECASTON.
BIRMINGHAM
B69 0PW.

Patents ADP number (if you know it)

PPS/17
14/7/03

8158429003

6. If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an
applicant, or
- c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
 Do not count copies of the same document

| | |
|----------------------------------|---------------------|
| Continuation sheets of this form | NONE |
| Description | 17 PAGES <i>(R)</i> |
| Claim(s) | NONE |
| Abstract | NONE |
| Drawing(s) | NONE |

10. If you are also filing any of the following, state how many against each item.

| | |
|------------------------------------------------------------------------------|------------------------------------|
| Priority documents | NONE |
| Translations of priority documents | NONE |
| Statement of inventorship and right to grant of a patent (Patents Form 7/77) | NONE |
| Request for preliminary examination and search (Patents Form 9/77) | NONE |
| Request for substantive examination (Patents Form 10/77) | NONE |
| Any other documents (please specify) | <i>cover page to specification</i> |

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

14/07/2003

R G M SAVIDGE - By Power of Attorney

12. Name and daytime telephone number of person to contact in the United Kingdom

MR R G M SAVIDGE
0121 420 5868

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

STRUCTURED SURFACTANT SYSTEMS

The invention relates to structured surfactant systems and to suspensions of water-insoluble, or sparingly soluble, particles therein. In particular it relates to structured systems based on non-ionic surfactants, suitable for applications in which high levels of anionic surfactant are unacceptable.

The invention is especially relevant to pharmaceutical and veterinary suspensions, and in particular to aqueous structured surfactant systems capable of suspending water insoluble pharmaceutical and veterinary active materials for internal use. It is generally suitable for preparations intended for oral administration. Certain compositions according to the invention could also be administered parenterally.

The invention is also especially relevant to food and beverages which comprise a continuous liquid phase with suspended solids.

The invention is also relevant generally to the suspension of solids or water-immiscible liquids in aqueous, structured-liquid surfactants, for example in cleaning preparations, personal care formulations, agricultural or horticultural applications and for cement and paper additives.

The great majority of medicaments are taken orally, usually in the form of tablets, pills or capsules, despite the fact that many people, especially children, have difficulty swallowing them. It is probable that most people would prefer to take medicines in the form of a pleasant tasting liquid, if they were available in such a form. Moreover a pill or capsule can only deliver a fixed dose, and a tablet can only yield a partial dose by cutting, which is usually accompanied by some crushing, resulting in wastage and underdosing. A liquid, in contrast, can be dosed in any amount, to meet the requirements of individual patients.

The main reason why more medicines are not available in liquid form is that the majority are insoluble, or insufficiently soluble, in water or any other acceptable solvent. They could only be made available as suspensions. However medicinal suspensions undergo sedimentation on standing, leading to a risk of under or overdosing, if instructions to shake the bottle thoroughly are not fully complied with. A further problem is that only relatively low concentrations of solids can be suspended, without the product becoming unacceptably viscous. For these reasons the use of suspensions has largely been confined to paediatric medicine. Thus for example suspensions of paracetamol are widely used for treating infants, but no adult equivalent is available.

Sedimentation is also a problem in a variety of food and drink products, including fruit squashes, pulps, purees, preserves and canned fruit and vegetables.

Calcium stearate dispersions have been widely used, for many years, especially in the construction industry, as an additive to cement, to make the set product more water repellent, and also in the paper industry, to provide water repellent coatings to paper. They are also used as lubricants for abrasive coatings. Two long standing problems with such dispersions has been poor physical stability leading to separation of the solids, and the adverse effect, from the point of view of the end user, of the surfactants, and especially the anionic surfactants, used to improve their stability. Such surfactants have been used as dispersants, to render the particles more hydrophilic, by coating them with a monolayer of surfactant.

Attempts to solve the problem of dispersing solids in water have hitherto involved the use of gums or other polymeric thickeners to raise the viscosity of the liquid medium, or the formation of colloidal dispersions.

Gums and polymeric thickeners, which increase the viscosity of the liquid medium, retard, but do not prevent sedimentation, and at the same time make the composition harder to pour. They do not provide stable suspensions. Thus the paediatric suspensions of paracetamol, although fairly viscous, are not fully stable

Colloidal dispersions contain particles of about 1 micron or smaller, which are prevented from sedimenting by Brownian motion. However there are often problems in preventing the agglomeration, or crystal growth of colloidal particles. Most colloidal suspensions lack long term stability due to Ostwald ripening. For example attempts to provide stable colloidal suspensions of elemental selenium, to remedy dietary deficiencies in grazing animals have proved unsuccessful.

A further problem with colloidal particles is that, on account of their small size, they tend to dissolve rapidly, releasing the active ingredient within a short period after ingestion, whereas for most treatment regimes a slower, more controlled release is desirable.

An alternative to the above methods of suspension would be the use of a structured suspending system. Structured suspending systems depend on the rheological properties of the suspending medium to immobilise the particles, irrespective of size. This requires the suspending medium to exhibit a yield point, which is higher than the sedimenting or creaming force exerted by the suspended particles, but low enough to enable the medium to flow under externally imposed stresses, such as pouring and stirring, like a normal liquid. The structure reforms sufficiently rapidly to prevent sedimentation, once the agitation caused by the external stress has ceased.

The only structured systems, sufficiently effective to have found widespread application, have been based on surfactant mesophases. These, however, normally require relatively high concentrations of surfactant, usually anionic, and/or electrolyte, which are generally undesirable in medicinal suspensions or beverages. The use of structured surfactants has therefore been largely confined to cleaning preparations, such as laundry detergents and scouring creams.

The term "structured system" as used herein means a pourable composition comprising water, surfactant, any structurants, which may be required to provide suspending properties and optionally other dissolved matter, which together form a

mesophase, or a dispersion of a mesophase in a continuous aqueous medium, and which has the ability to immobilise non-colloidal, water- insoluble particles, while the system is at rest, thereby forming a stable, pourable suspension.

Three main types of structured system have been employed in practice, all involving an L_α -phase, in which bilayers of surfactant are arranged with the hydrophobic part of the molecule on the interior and the hydrophilic part on the exterior of the bilayer (or vice versa). The bilayers lie side by side, e.g. in a parallel or concentric configuration, sometimes separated by aqueous layers. L_α -phases (also known as G- phases) can usually be identified by their characteristic textures under the polarising microscope and/or by x-ray diffraction, which is often able to detect evidence of lamellar symmetry. Such evidence may comprise first, second and sometimes third order peaks with a d-spacing ($\frac{2\pi}{Q}$, where Q is the momentum transfer vector) in a simple

integral ratio 1:2:3. Other types of symmetry give different ratios, usually non-integral. The d-spacing of the first peak in the series corresponds to the repeat spacing of the bilayer system.

Most surfactants form an L_α -phase either at ambient or at some higher temperature when mixed with water in certain specific proportions. However such conventional L_α -phases do not usually function as structured suspending systems. Useful quantities of solid render them unpourable and smaller amounts tend to sediment.

The main types of structured system used in practice are based on dispersed lamellar, spherulitic and expanded lamellar phases. Dispersed lamellar phases are two phase systems in which the surfactant bilayers are arranged as parallel plates to form domains of L_α -phase, which are interspersed with an aqueous phase to form an opaque gel-like system. They are described in EP O 086 614.

Spherulitic phases comprise well-defined spheroidal bodies, usually referred to in the art as spherulites, in which surfactant bilayers are arranged as concentric shells. The spherulites usually have a diameter in the range 0.1 to 15 microns and are dispersed in

an aqueous phase in the manner of a classical emulsion, but interacting to form a structured system. Spherulitic systems are described in more detail in EP O 151 884. Many structured systems are intermediate between dispersed lamellar and spherulitic, involving both types of structure. Usually systems having a more spherulitic character are preferred because they tend to have lower viscosity. A variant on the spherulitic system comprises prolate or rod shaped bodies sometimes referred to as batonettes. These are normally too viscous to be of practical interest.

Both of the foregoing systems comprise two phases. Their stability depends on the presence of sufficient dispersed phase to pack the system so that the interaction between the spherulites or other dispersed mesophase domains prevents separation. If the amount of dispersed phase is insufficient, e.g. because there is not enough surfactant or because the surfactant is too soluble in the aqueous phase to form sufficient of a mesophase, the system will undergo separation and cannot be used to suspend solids. Such unstable systems are not "structured" for the purpose of this specification.

A third type of structured system comprises an expanded L_a -phase. It differs from the other two types of structured system in being essentially a single phase, and from conventional L_a -phase in having a wider d-spacing. Conventional L_a -phases, which typically contain 60 to 75% by weight surfactant, have a d-spacing of about 4 to 7 nanometers. Attempts to suspend solids in such phases result in stiff pastes which are either non-pourable, unstable or both. Expanded L_a -phases with d-spacing greater than 8, e.g. 10 to 15 nanometers, form when electrolyte is added to aqueous surfactants at concentrations just below those required to form a normal L_a -phase, particularly to surfactants in the H-phase.

The H-phase comprises surfactant molecules arranged to form cylindrical rods of indefinite length. It exhibits hexagonal symmetry and a distinctive texture under the polarising microscope. Typical H-phases have so high a viscosity that they appear to be curdy solids. H-phases near the lower concentration limit (the L_i /H-phase boundary) may be pourable but have a very high viscosity and often a mucous-like

appearance. Such systems tend to form expanded L_a -phases particularly readily on addition of sufficient electrolyte.

Expanded L_a -phases are described in more detail in EP O 530 708. In the absence of suspended matter they are translucent, unlike dispersed lamellar or spherulitic phases which are normally opaque. They are optically anisotropic and have shear dependent viscosity. In this they differ from L_1 -phases, which are micellar solutions and which include microemulsions. L_1 -phases are clear, optically isotropic and are usually substantially Newtonian. They are unstructured and cannot suspend solids.

Some L_1 -phases exhibit small angle x-ray diffraction spectra which show evidence of hexagonal symmetry and/or exhibit shear dependent viscosity. Such phases usually have concentrations near the L_1 /H-phase boundary and may form expanded L_a -phases on addition of electrolyte. However in the absence of any such addition of electrolyte they lack the yield point required to provide suspending properties, and are not, therefore, "structured systems" for the purpose of this specification.

Expanded L_a -phases of the above type are usually less robust than spherulitic systems. They are liable to become unstable at low temperatures. Moreover they frequently exhibit a relatively low yield stress, which may limit the maximum size of particle that can be stably suspended.

Most structured surfactants require the presence of a structurant, as well as surfactant and water in order to form structured systems capable of suspending solids. The term "structurant" is used herein to describe any non-surfactant capable, when dissolved in water, of interacting with surfactant to form a structured system. It is typically a surfactant-desolubiliser, e.g. an electrolyte. However, certain relatively hydrophobic surfactants such as isopropylamine alkyl benzene sulphonate can form spherulites in water in the absence of electrolyte. Such surfactants are capable of suspending solids in the absence of any structurant, as described in EP O 414 549. Unfortunately isopropylamine alkyl benzene sulphonate is not a pharmacologically acceptable surfactant.

A problem with the two phase, especially spherulitic, systems, is flocculation of the dispersed surfactant structures. This tends to occur at high surfactant and/or high electrolyte concentration. It can have the effect of making the composition very viscous and/or unstable with the dispersed surfactant separating from the aqueous phase.

Certain amphiphilic polymers have been found to act as deflocculants of structured surfactants. One type of deflocculant polymer exhibits cteniform (comb-shaped) architecture with a hydrophilic backbone and hydrophobic side chains or vice versa. A typical example is a random copolymer of acrylic acid and a fatty alkyl acrylate. Cteniform deflocculants have been described in a large number of patents, for example WO-A-9106622.

A more effective type of deflocculant has surfactant (linear) rather than cteniform architecture, with a hydrophilic polymer group attached at one end to a hydrophobic group. Such deflocculants are typically telomers formed by telomerising a hydrophilic monomer with a hydrophobic telogen. Examples of surfactant deflocculants include alkyl thiol polyacrylates and alkyl polyglycosides. Surfactant deflocculants are described in more detail in EP O 623 670.

WO 01/00788 describes the use of carbohydrates such as sugars and alginates as deflocculants in structured surfactant compositions. The latter comprise surfactant, water and electrolyte in proportions adapted to form flocculated two-phase structured surfactant systems in the absence of the carbohydrate.

The use of deflocculant polymers can give rise to syneresis. The spherulitic suspending medium shrinks in volume leaving a clear portion of the continuous phase external to the spherulitic suspending medium. In conventional, aqueous, structured systems, in which the surfactant is normally less dense than the aqueous phase, this usually manifests itself as a clear lower layer ("bottom separation"). Various auxiliary stabilisers have been suggested to inhibit or prevent syneresis or bottom

separation of structured surfactant. For example US 5 602 092 has proposed the use of highly cross linked polyacrylates, while WO 01/00779 describes the use as auxiliary stabiliser of non-cross linked polymers with a hydrophilic back bone and sufficient short (e.g. C₁₋₅) hydrocarbon side chains to enhance physical entanglement of the polymer molecules, e.g. polymers of acrylic acid with ethyl acrylate.

Clays such as bentonite or synthetic layered silicates have also been used as auxiliary stabilisers, either alone or in conjunction with polymers.

The use of deflocculant polymers to prepare clear spherulitic or other dispersed L_α structured systems by shrinking the spherulites or other L_α domains to a size below the wave length of visible light has been described in WO 00/63079, which also describes the use of sugar to modify the refractive index of the aqueous phase as an alternative means of obtaining clear liquids.

It is known from WO 01/05932 that carbohydrates can interact with surfactants to form suspending structures. Such systems generally exhibit even greater d-spacings than the electrolyte-structured expanded L_α-phases, described in EP 0 530 708. The d-spacings of the sugar-structured systems, described in WO 01/05932, may be up to 50nm.

In many applications, and especially for pharmacologically acceptable products, and for food and drink, non-ionic surfactants are strongly preferred. However structured systems based on non-ionic surfactants tend to exhibit poor temperature stability at elevated temperatures. They undergo a phase change, on storage under warm conditions, to give non-suspending L₂-phases. WO 01/00780 describes the use of high molecular weight ethoxylates in conjunction with thiocyanates as auxiliary stabilisers inhibiting or preventing loss of structure at elevated temperatures, however thiocyanate is not an acceptable ingredient of products intended for ingestion.

We have now discovered non-ionic based structured surfactant systems with improved temperature stability, which, in a preferred embodiment, are capable of

being formulated with pharmacologically acceptable ingredients, and of stably suspending medicaments for internal use.

We have found that structured surfactants formed from mixtures of non-ionic surfactants having hydrophobic groups with predominantly bent chains are more stable at elevated temperatures than conventional non-ionic systems.

As used herein the expression "bent chain" refers to a hydrocarbon chain, which has a dihedral form resulting from the presence of a single non-linear feature, preferably at or near the middle of the chain. Examples of non-linear features include cis double bonds, short chain (e.g. methyl or ethyl) branching, or carbonyl groups. In contrast, trans double bonds, or combinations of two or more non-linear features, give chains that are kinked rather than bent. The non-linear group is preferably located at or near the middle of the chain, i.e. at least two, preferably at least three, more preferably at least four, most preferably at least five, carbon atoms from the non-functional end of the chain, and preferably also from the functional, i.e. hydrophilic end.

According to a first embodiment, the invention provides an aqueous based structured surfactant system, having solid-suspending properties and comprising: water; from 2 to 35%, by weight, based on the weight of the system, of surfactants; said surfactants consisting essentially of non-ionic surfactants, each comprising a hydrophobic group and a non-ionic hydrophilic group; characterised in that at least 30% by weight of said hydrophobic groups are bent chain groups.

According to a preferred embodiment, the invention provides a structured surfactant system as aforesaid, for suspending water insoluble pharmaceutical or veterinary active ingredients, which consists essentially of: water; from 0% to saturation of a dissolved carbohydrate; from 0 to 10% by weight, based on the weight of the suspending system, of electrolyte; and from 3 to 10% by weight, based on the weight of the suspending system, of a surfactant mixture consisting of (A) a pharmacologically or veterinarily acceptable surfactant, having an HLB greater than 10, which is preferably an ethoxylated sorbitan ester and (B) a pharmacologically or

veterinarily acceptable surfactant, with a HLB less than 10, which is preferably a monoglyceride ester in a weight ratio of from 10:1 to 1:1, (A):(B).

According to a second preferred embodiment, the invention provides a food product or beverage comprising a continuous aqueous liquid phase, and suspended, non-colloidal solid, characterised in that said aqueous phase is a structured surfactant system as aforesaid, which consists essentially of: water; from 25% by weight, based on the weight of the suspending system, to saturation of a dissolved carbohydrate structurant; from 0 to 10% by weight, based on the weight of the suspending system, of electrolyte; and from 3 to 10% by weight, based on the weight of the suspending system, of a surfactant mixture consisting of (A) an edible surfactant, having an HLB greater than 10, which is preferably a ethoxylated sorbitan ester and (B) an edible surfactant, with a pH less than 10, which is preferably a monoglyceride ester, in a weight ratio of from 10:1 to 1:1, (A):(B).

We have also observed that our preferred suspending systems have a substantially higher d-spacing than those of the prior art.

According to a further embodiment, therefore, the invention provides a structured surfactant suspending system comprising water, a dissolved structurant, which is preferably a carbohydrate, and a surfactant, characterised by a small angle X-ray diffraction peak corresponding to a d-spacing greater than 50nm.

According to further embodiments, the invention provides a method of suspending pharmaceutical or veterinary active ingredients in a structured surfactant system as aforesaid, and suspensions so formed, and methods of preparing such suspensions in dose form for oral use.

In the following discussion of the invention, unless stated to the contrary, the disclosure of alternative values for the upper or lower limit of the permitted range of a parameter, coupled with an indication that one of said values is more highly preferred than the other, is to be construed as an implied statement that each intermediate value

of said parameter, lying between the more preferred and the less preferred of said alternatives, is itself preferred to said less preferred value and also to each value lying between said less preferred value and said intermediate value.

The proportion of bent chain hydrophobic groups is preferably greater than 40%, more preferably greater than 50%, even more preferably greater than 60%, more preferably still, greater than 75%, most preferably greater than 90%, based on the total weight of hydrophobic groups in the surfactant. The preferred bent chain groups are oleyl, erucyl and isostearyl.

The total proportion of surfactant is preferably greater than 3% more preferably greater than 5%, even more preferably greater than 6% most preferably greater than 7% by weight, based on the total weight of surfactant and water, but preferably less than 30% more preferably less than 20%, even more preferably less than 15%, most preferably less than 10%.

The non-ionic surfactants may typically comprise polyglyceryl fatty esters, fatty acid ethoxylates, fatty acid monoalkanolamides, fatty acid dialkanolamides, fatty acid alkanolamide ethoxylates, propylene glycol monoesters, fatty alcohol propoxylates, alcohol ethoxylates, alkyl phenol ethoxylates, fatty amine alkoxylates and fatty acid glyceryl ester ethoxylates. Other non-ionic compounds suitable for inclusion in compositions of the present invention include mixed ethylene oxide/ propylene oxide block copolymers, ethylene glycol monoesters, alkyl polyglycosides, alkyl sugar esters including alkyl sucrose esters and alkyl oligosaccharide esters, sorbitan esters, ethoxylated sorbitan esters, alkyl capped polyvinyl alcohol and alkyl capped polyvinyl pyrrolidone. We particularly prefer surfactants that are approved for pharmacological use.

The surfactants preferably have a mean HLB greater than 6.5, more preferably greater than 7.5, even more preferably greater than 8, more preferably still, greater than 8.5, most preferably greater than 9, but less than 13, more preferably less than 12, even more preferably less than 12.5, most preferably less than 11. We particularly prefer

the non-ionic surfactant comprises a mixture of at least one relatively high HLB surfactant with at least one relatively low HLB surfactant.

The high HLB surfactant is preferably an ethoxylated sorbitan ester, but could alternatively comprise, for example a sucrose or polyglyceryl ester, or ethoxylated castor oil. The ester may be an ester of a C₆₋₂₅, saturated or unsaturated, bent chain fatty acid, such as oleic, erucic or isostearic. It preferably has an HLB greater than 10, more preferably greater than 12, even more preferably greater than 14, most preferably greater than 15, but preferably less than 19, more preferably less than 18, most preferably less than 17.

The low HLB surfactant is preferably a monoglyceride ester surfactant or, less preferably, a sorbitan ester, a lactic or acetic acid ester of a monoglyceride or a polyglyceryl ester of a fatty acid. Particularly preferred are esters with C₁₀₋₂₅ bent chain fatty acids such as, oleic, erucic or isostearic. The low HLB surfactant preferably has an HLB less than 8, more preferably less than 7, even more preferably less than 6, most preferably less than 5.5, but preferably greater than 2, more preferably greater than 3, most preferably greater than 3.3.

The weight ratio of low HLB surfactant to high HLB surfactant is preferably less than 2:1, more preferably less than 1.5:1, most preferably less than 1:1, but preferably more than 1:10, more preferably more than 1:5, most preferably more than 1:3.

The surfactant system consists essentially of non-ionic surfactant. Although minor proportions of anionic, cationic and/or amphoteric surfactant may optionally be present, e.g. up to 30 % by weight of the total surfactant, for most purposes it is strongly preferred that ionic surfactants be substantially absent. If present they preferably constitute less than 15%, more preferably less than 10%, even more preferably less than 5%, more preferably still less than 2%, most preferably less than 1% by weight of the total surfactant.

Preferably the compositions of the invention comprise a carbohydrate. It has been found that, even where the surfactant system is sufficient to form a structured suspending system in the absence of carbohydrate, added carbohydrate tends to increase the yield point and suspending power and stability of the system.

The aqueous structured systems, formed by the interaction of surfactants with carbohydrates, include systems, which are believed to be in the form of an expanded L_a -phase. They include novel systems having an even wider d-spacing than the typical electrolyte-structured expanded L_a -phases described in EP O 530 708. The systems of the present invention comprise structures, which preferably show d-spacings greater than 20nm, more preferably greater than 50nm, even more preferably greater than 51nm, more preferably still, greater than 70nm, most preferably greater than 90nm. Preferably the d-spacing is less than 300nm, more preferably less than 200nm, most preferably less than 150nm. We do not exclude systems with d-spacings greater than 300nm, but such d-spacings are difficult to measure accurately, using conventional X-ray diffractometers, due to their proximity to the reference beam. Preferably the above d-spacings relate to the principal, only substantial or sole peak exhibited by the structured system, in the absence of suspended matter, at least above 1nm.

The discussion is based on the assumption that the structure is lamellar. We do not, however, intend to exclude the possibility that the system may comprise non-lamellar components.

The carbohydrate is preferably a mono or, more preferably, disaccharide sugar, most preferably sucrose, but could for example be fructose, maltose, glucose or invert sugar. Other sugars, which can be used, include, for example, mannose, ribose, galactose, lactose, allose, altrose, talose, gulose, idose, arabinose, xylose, lyxose, erythrose, threose, acrose, rhamnose, fucose, glyceraldehyde, stachyose, agavose and cellobiose. The carbohydrate may be a tri- or tetra-saccharide or, less preferably, a water soluble polysaccharide such as soluble starch, or a water soluble gum. The term "carbohydrate" as used herein includes water soluble non-surfactant derivatives of

carbohydrates such as carboxylic acids and their salts, which can be obtained by oxidising sugars, e.g. gluconic acid, mannic acid, ascorbic acid and alginates or alcohols obtained by reducing sugars such as sorbitol, mannitol or inositol.

The levels of carbohydrate may be sufficiently high to inhibit microbiological growth in the medium and sufficient to act as an effective biodegradable, non-allergenic preservative for the composition. The carbohydrate may additionally mask the taste of the active ingredient, and render the composition more palatable.

The carbohydrate may be present, optionally, in concentrations up to saturation, preferably greater than 3%, more preferably greater than 5%, even more preferably greater than 10%, most preferably greater than 15% by weight. Usually the concentration of carbohydrate is less than 75%, by weight, preferably less than 50%, most preferably less than 40%, by weight.

The composition may optionally contain an electrolyte, in concentrations up to saturation. The concentration of electrolyte is preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, e.g. 0 to 4%, by weight. The electrolyte is typically sodium chloride, but could, for example, alternatively or additionally, be or comprise, sodium carbonate, potassium chloride, sodium phosphate, or sodium citrate.

The suspending medium of the invention may be used to suspend any medicament, which is insufficiently soluble in water to be conveniently dosed as an aqueous solution. For example the suspended material may comprise one or more antibiotic, analgesic, antiviral, antihelmintic, antacid, anticonvulsant, antifungal, tranquiliser, sedative, anti-inflammatory, anti-histamine or tonic. It can be used to suspend animal food supplements, such as selenium particles, for veterinary use.

Depending on the yield-point of the suspending medium, the suspended material may have any convenient particle size, and is not limited to micron-sized particles, like

colloidal systems. This allows slower release in the body, as well as lower manufacturing costs.

A particular advantage of using structured surfactants to suspend pharmacologically active ingredients is the possibility of suspending particles of widely different sizes, allowing a control over the release rate of the active substance, or the relative release rates of two or more active substances, an effect that has hitherto only been possible using encapsulation.

According to a further embodiment the invention provides a pharmaceutical or veterinary suspension comprising a pharmacologically or veterinarian acceptable structured surfactant and suspended particles of at least one pharmacological or veterinary active substance, said particles comprising at least two populations differentiated with respect to size and including a first population, of non-colloidal particles comprising at least 10%, preferably at least 20%, more preferably at least 30% by weight, based on the total weight of the particles, and a second population of particles comprising at least 10%, preferably at least 20%, more preferably at least 30%, by weight, based on the total weight of the particles, wherein said first population has a mean particle size at least ten times, preferably at least fifty times, more preferably at least 100 times, even more preferably at least 200 times, most preferably at least 500 times the mean particle size of said second population.

The suspension may alternatively, for example, be a food or beverage, a detergent, in which the suspended particles may comprise a builder and/or silicone antifoam, a hard surface cleaner comprising a suspended abrasive, a personal care formulation, comprising personal care active ingredients, such as talc, titanium oxide, vegetable oil, silicone oil, exfoliants, pigments and topical medicaments, an agrochemical composition comprising e.g. pesticides, weed-killers or fertilisers or a suspension of calcium stearate for use as a cement additive.

The invention will be illustrated by the following examples, in which all proportions are % by weight unless stated to the contrary.

EXAMPLE I

A paediatric analgesic suspension comprised:

| | |
|------------------------------------|---------|
| Paracetamol | 2.4 |
| Sorbitan 20 mole ethoxy monooleate | 10 |
| Glyceryl monooleate | 5 |
| Sucrose | 15 |
| Water | balance |

The product was a stable, non-sedimenting suspension. The suspended material had particles ranging in size from 5 to 100 μ , compared to a narrow range of about 7 μ , which is required to make colloidal dispersions.

EXAMPLE II

An animal feed supplement comprised:

| | |
|---------------------------------------|---------|
| Selenium particles-100mesh (5 μ) | 1 |
| Sorbitan 20 mole ethoxy monooleate | 10 |
| Glyceryl monooleate | 5 |
| Sucrose | 15 |
| Water | balance |

The above formulation was a clear thin structured liquid with a d-spacing of about 120nm, and was stable after three weeks storage

EXAMPLE III

A fruit drink comprised:

| | |
|-----------------------|---------|
| Sorbitan monooleate | 1.4 |
| Sucrose monooleate | 4.3 |
| Sucrose | 50 |
| Sodium chloride | 4 |
| Squeezed orange juice | balance |

The product was a stable, non-sedimenting suspension.

EXAMPLE IV

A composition was prepared consisting of:

| | |
|---------------------------------|---------|
| Oleyl alcohol 6 mole ethoxylate | 2% |
| Lauric acid 9 mole ethoxylate | 1% |
| Calcium stearate | 40% |
| Water | balance |

The mixture was a stable, pourable, spherulitic suspension with good compatibility with cement.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.